Samjo Management’s HTG Molecular Diagnostics HTGM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
– Sell
-33,747
Closed -$563K – 21
2022
Q1
$563K Sell
33,747
-15,420
-31% -$495K 0.48% 19
2021
Q4
$3.2M Sell
49,167
-5,833
-11% -$340K 2.14% 12
2021
Q3
$3.77M Buy
55,000
+10,500
+24% +$751K 2.77% 13
2021
Q2
$3.1M Buy
44,500
+8,667
+24% +$469K 2.1% 14
2021
Q1
$2.35M Buy
35,833
+4,024
+13% +$305K 1.74% 15
2020
Q4
$1.83M Hold
31,809
– – 1.56% 12

Other funds holding HTGM

Samjo Management's HTGM Position: Q2 2022 in Review

Samjo Management sold out of HTG Molecular Diagnostics (HTGM) in Q2 2022, closing a stake of 33,747 shares — an estimated $563K sold.

Samjo Management first reported a position in HTGM in Q4 2020 and held it in 6 quarters. The position peaked at $3.77M in Q3 2021. 21 funds tracked by Wall St. Rank hold HTGM as of Q2 2022.

  • Samjo Management reported no remaining HTG Molecular Diagnostics position as of Q2 2022 after selling out during the quarter.
  • Samjo Management sold 33,747 HTG Molecular Diagnostics shares in Q2 2022, an estimated $563K.
  • Samjo Management first reported a position in HTG Molecular Diagnostics in Q4 2020 and held it in 6 quarters.
  • Samjo Management's HTG Molecular Diagnostics position peaked at $3.77M in Q3 2021.
  • 21 funds tracked by Wall St. Rank held HTG Molecular Diagnostics as of Q2 2022.

Based on Samjo Management's 13F filing for Q2 2022, filed 4 Aug 2022.